Biggest News Aggregation in the World
📰 Genentech News

Page 127 - Genentech News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss - Roche Holding (OTC:RHHBY)

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) – ‒ Real-world data reinforce that first-line
United States Levi Garraway Clinical Development Program Roche Group American Society Of Retina Specialists Global Product Development

New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss - Roche Holding (OTC:RHHBY)

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-line Vabysmo use
United States United Kingdom City Of Levi Garraway European Medicines Agency European Union

New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...
United States United Kingdom South San Francisco Danielle Haney Adam Pryor Levi Garraway

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science